Chemical Compound Review:
Piritrexim 9-[(2,5- dimethoxyphenyl)methyl]-10- methyl...
Synonyms:
Piritrexima, Piritrexime, Piritreximum, CHEMBL7492, SureCN8124, ...
- Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Adamson, P.C., Balis, F.M., Miser, J., Arndt, C., Wells, R.J., Gillespie, A., Aronson, L., Penta, J.S., Clendeninn, N.J., Poplack, D.G. Cancer Res. (1992)
- Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. Feun, L.G., Gonzalez, R., Savaraj, N., Hanlon, J., Collier, M., Robinson, W.A., Clendeninn, N.J. J. Clin. Oncol. (1991)
- Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. Rosowsky, A., Forsch, R.A., Queener, S.F. J. Med. Chem. (2002)
- 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. Rosowsky, A., Mota, C.E., Wright, J.E., Freisheim, J.H., Heusner, J.J., McCormack, J.J., Queener, S.F. J. Med. Chem. (1993)
- A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer. de Vries, E.G., Gietema, J.A., Workman, P., Scott, J.E., Crawshaw, A., Dobbs, H.J., Dennis, I., Mulder, N.H., Sleijfer, D.T., Willemse, P.H. Br. J. Cancer (1993)
- Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Adamson, P.C., Balis, F.M., Miser, J., Wells, R.J., Bleyer, W.A., Williams, T.E., Gillespie, A., Penta, J.S., Clendeninn, N.J., Poplack, D.G. Cancer Res. (1990)
- Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine. Assaraf, Y.G., Slotky, J.I. J. Biol. Chem. (1993)
- Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. Assaraf, Y.G., Molina, A., Schimke, R.T. J. Biol. Chem. (1989)
- Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties. Ercikan-Abali, E.A., Waltham, M.C., Dicker, A.P., Schweitzer, B.I., Gritsman, H., Banerjee, D., Bertino, J.R. Mol. Pharmacol. (1996)
- Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain. Chan, D.C., Fu, H., Forsch, R.A., Queener, S.F., Rosowsky, A. J. Med. Chem. (2005)
- Drug concentration-dependent DNA lesions are induced by the lipid-soluble antifolate, piritrexim (BW301U). Richards, R.G., Brown, O.E., Gillison, M.L., Sedwick, W.D. Mol. Pharmacol. (1986)
- Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Vokes, E.E., Haraf, D.J., McEvilly, J.M., Mick, R., Kozloff, M.F., Goldman, M.D., Moran, W.J., Clendeninn, N.J., Collier, M.A., Weichselbaum, R.R. Ann. Oncol. (1992)
- Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist. Guzzo, C., Benik, K., Lazarus, G., Johnson, J., Weinstein, G. Archives of dermatology. (1991)
- Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. Huie, M., Carducci, M., Liu, G., Wilding, G., Marnocha, R., Izquierda, M., Thomas, J. Am. J. Clin. Oncol. (2005)
- 2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. Rosowsky, A., Forsch, R.A., Queener, S.F. J. Med. Chem. (1995)
- Competitive protein binding assay for piritrexim. Woolley, J.L., Ringstad, J.L., Sigel, C.W. Journal of pharmaceutical sciences. (1989)
- Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype. Assaraf, Y.G., Borgnia, M.J. Anticancer Drugs (1993)
- QSAR studies on biological activity of piritrexim analogues against pc DHFR. Agrawal, V.K., Sohgaura, R., Khadikar, P.V. Bioorg. Med. Chem. (2002)
- Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Kovacs, J.A., Allegra, C.J., Swan, J.C., Drake, J.C., Parrillo, J.E., Chabner, B.A., Masur, H. Antimicrob. Agents Chemother. (1988)
- In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Viora, M., De Luca, A., D'Ambrosio, A., Antinori, A., Ortona, E. Antimicrob. Agents Chemother. (1996)
- Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group. Roth, B.J., Manola, J., Dreicer, R., Graham, D., Wilding, G. Investigational new drugs. (2002)
- Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. Piper, J.R., Johnson, C.A., Krauth, C.A., Carter, R.L., Hosmer, C.A., Queener, S.F., Borotz, S.E., Pfefferkorn, E.R. J. Med. Chem. (1996)
- Mechanisms of inhibition of amido phosphoribosyltransferase from mouse L1210 leukemia cells. Schoettle, S.L., Crisp, L.B., Szabados, E., Christopherson, R.I. Biochemistry (1997)
- The disposition and metabolism of [14C]piritrexim in rats after intravenous and oral administration. Woolley, J.L., Deangelis, D.V., Crouch, R.C., Shockcor, J.P., Sigel, C.W. Drug Metab. Dispos. (1991)
- Gemcitabine, Paclitaxel, and piritrexim: a phase I study. Liu, G., Bailey, H.H., Arzoomanian, R.Z., Alberti, D., Binger, K., Volkman, J., Feierabend, C., Marnocha, R., Wilding, G., Thomas, J.P. Am. J. Clin. Oncol. (2003)
- Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates. Gangjee, A., Zeng, Y., McGuire, J.J., Kisliuk, R.L. J. Med. Chem. (2002)
- High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. Kuyper, L.F., Baccanari, D.P., Jones, M.L., Hunter, R.N., Tansik, R.L., Joyner, S.S., Boytos, C.M., Rudolph, S.K., Knick, V., Wilson, H.R., Caddell, J.M., Friedman, H.S., Comley, J.C., Stables, J.N. J. Med. Chem. (1996)
- Piritrexim (ILEX Oncology). Fraser, J.A., Bartlett, J. IDrugs : the investigational drugs journal. (1999)
- Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells. Lyons, S.D., Christopherson, R.I. Biochem. Int. (1991)
- Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. Feun, L.G., Savaraj, N., Benedetto, P., Hanlon, J., Sridhar, K.S., Collier, M., Richman, S., Liao, S.H., Clendeninn, N.J. J. Natl. Cancer Inst. (1991)
- Separation and determination of the antitumor drug piritrexim by molecularly imprinted microspheres in high-performance liquid chromatography. Lai, J.P., He, X.W., Chen, F. Analytical and bioanalytical chemistry. (2003)